Chiome Bioscience Inc.
4583.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥118 | ¥113 | ¥139 | ¥358 |
| % Growth | 4.4% | -18.5% | -61.3% | – |
| Cost of Goods Sold | ¥53 | ¥55 | ¥58 | ¥145 |
| Gross Profit | ¥65 | ¥58 | ¥81 | ¥213 |
| % Margin | 55.3% | 51.5% | 58.1% | 59.5% |
| R&D Expenses | ¥190 | ¥192 | ¥204 | ¥193 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥143 | ¥138 | ¥141 | ¥130 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | -¥0 |
| Operating Expenses | ¥334 | ¥330 | ¥345 | ¥323 |
| Operating Income | -¥269 | -¥272 | -¥265 | -¥110 |
| % Margin | -227.5% | -240.7% | -190.7% | -30.7% |
| Other Income/Exp. Net | ¥9 | -¥1 | -¥1 | ¥5 |
| Pre-Tax Income | -¥259 | -¥273 | -¥265 | -¥105 |
| Tax Expense | ¥1 | ¥1 | ¥1 | ¥1 |
| Net Income | -¥260 | -¥274 | -¥266 | -¥105 |
| % Margin | -220.3% | -242.5% | -191.8% | -29.4% |
| EPS | -3.82 | -4.04 | -3.94 | -1.65 |
| % Growth | 5.4% | -2.5% | -138.8% | – |
| EPS Diluted | -3.82 | -4.04 | -3.94 | -1.65 |
| Weighted Avg Shares Out | 68 | 68 | 68 | 64 |
| Weighted Avg Shares Out Dil | 68 | 68 | 68 | 64 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥1 | ¥0 | ¥1 | ¥0 |
| Interest Expense | ¥1 | ¥1 | ¥1 | ¥1 |
| Depreciation & Amortization | ¥1 | ¥0 | ¥0 | ¥0 |
| EBITDA | -¥257 | -¥272 | -¥264 | -¥110 |
| % Margin | -217.7% | -240.8% | -190.6% | -30.6% |